Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer release_3btkgpyngzgw5bfzzbwq6zh6te

by Morgan Craig, Kamran Kaveh, Alec Woosley, Andrew S. Brown, David Goldman, Elliot Eton, Ravindra M. Mehta, Andrew Dhawan, Kazuya Arai, M. Mamunur Rahman, Sidi Chen, Martin A. Nowak (+1 others)

Published in PLoS Computational Biology by Public Library of Science (PLoS).

2019   Volume 15, Issue 8, e1007278

Abstract

Understanding intrinsic and acquired resistance is crucial to overcoming cancer chemotherapy failure. While it is well-established that intratumor, subclonal genetic and phenotypic heterogeneity significantly contribute to resistance, it is not fully understood how tumor sub-clones interact with each other to withstand therapy pressure. Here, we report a previously unrecognized behavior in heterogeneous tumors: cooperative adaptation to therapy (CAT), in which cancer cells induce co-resistant phenotypes in neighboring cancer cells when exposed to cancer therapy. Using a CRISPR/Cas9 toolkit we engineered phenotypically diverse non-small cell lung cancer (NSCLC) cells by conferring mutations in Dicer1, a type III cytoplasmic endoribonuclease involved in small non-coding RNA genesis. We monitored three-dimensional growth dynamics of fluorescently-labeled mutant and/or wild-type cells individually or in co-culture using a substrate-free NanoCulture system under unstimulated or drug pressure conditions. By integrating mathematical modeling with flow cytometry, we characterized the growth patterns of mono- and co-cultures using a mathematical model of intra- and interspecies competition. Leveraging the flow cytometry data, we estimated the model's parameters to reveal that the combination of WT and mutants in co-cultures allowed for beneficial growth in previously drug sensitive cells despite drug pressure via induction of cell state transitions described by a cooperative game theoretic change in the fitness values. Finally, we used an ex vivo human tumor model that predicts clinical response through drug sensitivity analyses and determined that cellular and morphologic heterogeneity correlates to prognostic failure of multiple clinically-approved and off-label drugs in individual NSCLC patient samples. Together, these findings present a new paradox in drug resistance implicating non-genetic cooperation among tumor cells to thwart drug pressure, suggesting that profiling for druggable targets (i.e. mutations) alone may be insufficient to assign effective therapy.
In text/plain format

Archived Files and Locations

application/pdf  2.5 MB
file_wn5gz5rsubbctngrt74rtjg254
journals.plos.org (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2019-08-26
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  1553-734X
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: f5cceffa-0162-40bb-b298-cb4994fa3f09
API URL: JSON